- Home
- BMBL vs PHAR Comparison
BMBL vs PHAR Comparison
Compare BMBL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMBL
- PHAR
- Stock Information
- Founded
- BMBL 2014
- PHAR 1988
- Country
- BMBL United States
- PHAR Netherlands
- Employees
- BMBL 1200
- PHAR N/A
- Industry
- BMBL Computer Software: Prepackaged Software
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- BMBL Technology
- PHAR Health Care
- Exchange
- BMBL Nasdaq
- PHAR Nasdaq
- Market Cap
- BMBL 828.7M
- PHAR 679.0M
- IPO Year
- BMBL 2021
- PHAR N/A
- Fundamental
- Price
- BMBL $7.66
- PHAR $9.55
- Analyst Decision
- BMBL Hold
- PHAR Strong Buy
- Analyst Count
- BMBL 16
- PHAR 3
- Target Price
- BMBL $8.58
- PHAR $27.00
- AVG Volume (30 Days)
- BMBL 2.0M
- PHAR 5.4K
- Earning Date
- BMBL 02-25-2025
- PHAR 03-13-2025
- Dividend Yield
- BMBL N/A
- PHAR N/A
- EPS Growth
- BMBL N/A
- PHAR N/A
- EPS
- BMBL N/A
- PHAR N/A
- Revenue
- BMBL $1,083,632,000.00
- PHAR $285,745,000.00
- Revenue This Year
- BMBL $3.82
- PHAR $20.08
- Revenue Next Year
- BMBL N/A
- PHAR $9.22
- P/E Ratio
- BMBL N/A
- PHAR N/A
- Revenue Growth
- BMBL 6.26
- PHAR 30.64
- 52 Week Low
- BMBL $4.80
- PHAR $6.65
- 52 Week High
- BMBL $14.65
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- BMBL 44.17
- PHAR 50.97
- Support Level
- BMBL $7.59
- PHAR $9.37
- Resistance Level
- BMBL $8.51
- PHAR $10.01
- Average True Range (ATR)
- BMBL 0.44
- PHAR 0.52
- MACD
- BMBL -0.02
- PHAR -0.10
- Stochastic Oscillator
- BMBL 28.46
- PHAR 28.08
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.